Immunocytochemical determination of cell type and proliferation rate in human vein graft stenoses.
OBJECTIVE
Vascular reconstructions are prone to fail as a result of the development of stenotic lesions, which have historically been attributed to myointimal hyperplasia. In animal models, these lesions are associated with marked proliferative smooth muscle cell (SMC) response to vascular injury. However, recent studies using sensitive immunocytochemical techniques in human lesions have generally failed to detect significant cellular proliferation. To clarify the role of cellular proliferation in humans, we characterized the cellular composition and proliferative index of 14 early infrainguinal vein graft stenoses.


METHODS
All infrainguinal vein grafts at our institution are prospectively enrolled in a duplex surveillance protocol, the details of which have been previously reported. Among 98 grafts placed within the last year, 11 patients were identified with 14 progressive, focal, high-grade lesions that met previously established threshold criteria for prophylactic revision to prevent graft thrombosis. Lesions were first detected from 1 week to 7 months after surgery and were removed and replaced with segmental interposition grafts (1.5 to 10 months). Freshly excised lesions were placed in Methyl Carnoy's fixative, paraffin embedded, and serially sectioned. The cellular composition of each lesion was determined with cell-specific immunochemical reagents: alpha SMC actin, von Willebrand factor (endothelial cell), CD 68 (macrophage), and CD 45RB (monocyte). Actively proliferating cells were identified using antibody to proliferating cell nuclear antigen (PCNA). The identity of PCNA-positive cells was determined by double-label immunocytochemical staining, and the proliferative index (PCNA-positive cells/total cells x 100) was calculated by computer-assisted counts of representative gridded cross-sections of each lesion.


RESULTS
All excised lesions demonstrated marked thickening with severe luminal encroachment and were highly cellular, with a predominance of alpha SMC actin+. Endothelial cells on the blood flow surface were present to a variable degree, and seven lesions exhibited striking numbers of macrophages and monocytes. The latter cell types were most abundant near microvessels in the deep neointima and adventitia. Active cellular proliferation was identified primarily in SMCs, with a mean PCNA index of 1.34%. However, significant PCNA reactivity was not limited to SMCs, but was also identified in macrophages and monocytes, particularly in lesions greater than 3 months old.


CONCLUSIONS
Previous immunocytochemical studies of human coronary restenosis atherectomy specimens have generally detected low rates of cellular proliferation (0.5%), but these lesions may not truly represent myointimal hyperplasia, rather a mixture of atherosclerosis, thrombosis, and "restenosis." In contrast, the present study of early human vein graft lesions detected by duplex surveillance indicates that significant cellular proliferation occurs, although rates are lower than those obtained in animals such as the rat carotid injury model. In addition, although SMCs are the predominant proliferating cell type in human vein grafts, our identification of proliferating monocytes and macrophages raises the question of the contribution of an inflammatory component to the development of human lesions. The present study represents the first report of PCNA determination in a series of human infrainguinal vein grafting procedures.
Westerband
A
A
Section of Vascular Surgery and Vascular Biology, University of Arizona Health Sciences Center, Tuscon 85724, USA.
Mills
J L
JL
Marek
J M
JM
Heimark
R L
RL
Hunter
G C
GC
Williams
S K
SK
D002455:Cell Division; D006083:Graft Occlusion, Vascular / Q000000981:diagnostic imaging / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D018809:Proliferating Cell Nuclear Antigen; D011446:Prospective Studies; D014463:Ultrasonography
D018809:Proliferating Cell Nuclear Antigen